Guardant Health

Cancer care is evolving — and at Guardant Health, we’re continuing to advance what’s possible with comprehensive genomic profiling.   We pioneered the first FDA-approved comprehensive liquid biopsy. Now, we’re introducing the next evolution: Guardant360® Liquid CDx, the largest FDA-approved liquid biopsy panel, featuring a 100x expanded genomic and epigenomic footprint designed to deliver a more complete, actionable view of cancer from just a blood draw.    More details: https://lnkd.in/ehyfhqwh

We’re looking forward to joining the oncology nursing community this week at Oncology Nursing Society’s ONS Congress® 2026. Stop by booth 743 to connect with our team and learn how ctDNA testing and liquid biopsy insights are helping inform precision oncology.   We’ll also host two sessions of our educational event, From detection to decision: the role of ctDNA in oncology care, during the meeting:   Thursday, May 14, 2026 | 6:00 PM CT: https://bit.ly/4nwBC8z Friday, May 15, 2026 | 6:00 PM CT: https://bit.ly/42rEytu

At #MIGlobal, our chairman and co-CEO Helmy Eltoukhy discussed the next wave of health innovation and how advances in diagnostics, AI, and large-scale data are accelerating a shift toward earlier, more actionable cancer care. As Helmy shared, diagnostics already inform the majority of medical decisions, yet the healthcare system still invests far more heavily in treating disease after it progresses than detecting it earlier. The future of cancer care has to look different. Helmy shared a powerful example of what happens when technology compounds and the kind of progress that can help bend the healthcare cost curve. Watch the full session: https://bit.ly/48OKcte

Yesterday, we shared our first quarter 2026 financial results, with 48% year-over-year revenue growth driven by strong performance across our Oncology and Screening businesses.   This included significant growth across Guardant360® Liquid and Guardant360® Tissue testing, strong receptivity to our expansion into therapy response monitoring with Guardant Reveal®, and increasing Shield™ volumes as we continue working to bring precision oncology and cancer screening solutions to more patients.   More details: https://lnkd.in/ejSjbm_m

We’re excited to share that Guardant Health has been recertified as a Great Place To Work® in the U.S. for the fourth year in a row — a reflection of the people, purpose, and culture that drive us forward every day as we work to conquer cancer with data. Thank you to everyone across Guardant® whose passion, dedication, and collaboration make this recognition possible.

Leadership today is defined by more than outcomes. Later today, our co-CEO AmirAli Talasaz joins leaders at the Milken Institute Global Conference for an invite-only discussion on how reputation, trust, and culture are shaping resilient organizations. #MIGlobal session details: https://lnkd.in/eCEw7wtT

The next wave of health innovation is already taking shape. This afternoon, our Chairman and co-CEO Helmy Eltoukhy will join leaders at the Milken Institute Global Conference to discuss the technologies redefining what’s possible in healthcare—from AI-enabled discovery to multimodal data platforms and next-generation diagnostics. Turning these advances into impact will require clarity across regulation, sustainable models for access, and continued investment in innovation. Watch the #MIGlobal session live: https://lnkd.in/ggQmjRvC

We’re proud to share the FDA’s approval of Guardant360® CDx as a companion diagnostic for VEPPANU (vepdegestrant) for patients with ER+/HER2- advanced breast cancer with ESR1 mutations, marking our third ESR1 companion diagnostic FDA approval to help guide timely treatment decisions for patients with advanced breast cancer. “This latest FDA approval using Guardant360 CDx reflects where cancer care is headed using blood-based testing to detect resistance earlier and guide smarter treatment decisions,” added our chairman and co-CEO, Helmy Eltoukhy. “By identifying ESR1 mutations with just a simple blood draw, we’re helping bring more precise, personalized options to patients when they need them most.”

A collaboration shaped by the expanding role of precision diagnostics in oncology drug development. Today, we announced a multi-year collaboration with Nuvalent, Inc. to advance clinical development and companion diagnostic strategies using the tissue and liquid offerings of our Guardant Infinity™ platform—helping identify appropriate patient populations, improve trial efficiency, and support the development of targeted cancer therapies. More details: https://lnkd.in/emEfXFEu

#AACR26 brought a powerful week of progress for the cancer research community. From showcasing new data to connecting with researchers, clinicians, and partners from around the world, the conversations throughout the week reflected the momentum across cancer science and precision oncology. #ThankYou to everyone who stopped by, shared insights, and pushed the dialogue forward.